Evocalcet

Evocalcet
Clinical data
Trade names	Orkedia
ATC code	H05BX06 ( WHO );
Identifiers
	IUPAC name 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid;
CAS Number	870964-67-3 ;
PubChem CID	71242808 ;
DrugBank	DB12388 ;
UNII	E58MLH082P ;
KEGG	D11063 ;
CompTox Dashboard (EPA)	DTXSID101132784 ;
Chemical and physical data
Formula	C24H26N2O2
Molar mass	374.484 g·mol−1

Last updated September 29, 2025

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.^[1] It acts as a calcium-sensing receptor agonist.^[2]

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.^[3]

References

↑ Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4) e0195316. Bibcode:2018PLoSO..1395316K. doi: 10.1371/journal.pone.0195316 . PMC 5882164 . PMID 29614098.
↑ Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi: 10.1016/j.bmcl.2018.04.055 . PMID 29724589.
↑ "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.

This hormonal preparation article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4) e0195316. Bibcode:2018PLoSO..1395316K. doi: 10.1371/journal.pone.0195316 . PMC 5882164 . PMID 29614098.

[2] Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi: 10.1016/j.bmcl.2018.04.055 . PMID 29724589.

[3] "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.

[1]

[2]

[3]